Can a herbal supplement calm anxiety? new study puts motherwort to the test
NCT ID NCT06954038
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether a dietary supplement made from Leonurus cardiaca (motherwort) can reduce anxiety in adults with Generalized Anxiety Disorder. Sixty participants aged 20-50 will take either the supplement or a placebo for 30 days. Researchers will measure changes in anxiety, stress, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Leonurus cardiaca (motherwort) extract
- What this could lead to
- If it works, this could point toward a natural supplement option for reducing anxiety symptoms.
- What could go wrong
- This is a small, early pilot study with only 60 people. Results may not apply to everyone, and the supplement may not work better than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 20 to 50 years * Diagnosis of a generalised anxiety disorder (GAD), with manifestations occurring for \>= 6 months that include excessive worry, poor concentration, restlessness, muscle tension, irritability, fatigue and difficulty sleeping Exclusion Criteria: * Women who are pregnant or breastfeeding * Use of hormonal contraceptives in the last 3 months * Current diagnosis of major psychiatric disorders (e.g., major depressive disorder, severe anxiety disorders, schizophrenia, bipolar disorder) * Known endocrine disorders (e.g., hypothyroidism, hyperthyroidism, diabetes) * Use of medications that could affect mood or the menstrual cycle (e.g., SSRIs, anxiolytics, antipsychotics) * Severe hepatic or renal impairment * Any other serious or unstable medical condition that, in the investigator's judgment, could interfere with study participation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for General anxiety disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.